Randomized-controlled study of isophane and aspart insulin versus glargine and aspart insulin to treat prednisolone-induced hyperglycaemia in hospitalized patients

被引：0
|
作者：
Radhakutty, Anjana [1 ,2 ,3 ]
Stranks, Jessica L. [1 ]
Mangelsdorf, Brenda L. [1 ]
Drake, Sophie M. [1 ]
Roberts, Gregory W. [3 ,4 ]
Zimmermann, Anthony [2 ]
Stranks, Stephen N. [1 ]
Thompson, Campbell H. [3 ,5 ]
Burt, Morton G. [1 ,3 ]
机构：
[1] Repatriat Gen Hosp, Southern Adelaide Diabet & Endocrine Serv, Adelaide, SA, Australia
[2] Lyell McEwin Hosp, Endocrinol, Adelaide, SA, Australia
[3] Flinders Univ S Australia, Sch Med, Adelaide, SA, Australia
[4] Flinders Med Ctr, Dept Pharm, Adelaide, SA, Australia
[5] Univ Adelaide, Discipline Med, Adelaide, SA, Australia
来源：
CLINICAL ENDOCRINOLOGY | 2017年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
174
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [1] Treatment of prednisolone-induced hyperglycaemia in hospitalized patients: Insights from a randomized, controlled study
    Radhakutty, Anjana
    Stranks, Jessica L.
    Mangelsdorf, Brenda L.
    Drake, Sophie M.
    Roberts, Gregory W.
    Zimmermann, Anthony T.
    Stranks, Stephen N.
    Thompson, Campbell H.
    Burt, Morton G.
    DIABETES OBESITY & METABOLISM, 2017, 19 (04): : 571 - 578
  • [2] Efficacy of a basal bolus insulin protocol to treat prednisolone-induced hyperglycaemia in hospitalised patients
    Burt, M. G.
    Drake, S. M.
    Aguilar-Loza, N. R.
    Esterman, A.
    Stranks, S. N.
    Roberts, G. W.
    INTERNAL MEDICINE JOURNAL, 2015, 45 (03) : 261 - 266
  • [3] Efficacy and Safety of Insulin Degludec/Insulin Aspart versus Biphasic Insulin Aspart 30 in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
    Niu, Yan-Li
    Zhang, Ye
    Song, Zhi-Yong
    Zhao, Chuan-Zhi
    Luo, Yun
    Wang, Yan
    Yuan, Jing
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2024, 53 (02) : 313 - 322
  • [4] Continuous subcutaneous insulin infusion (CSII)of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII
    Hirsch, IB
    Bode, BW
    Garg, S
    Lane, WS
    Süssman, A
    Hu, P
    Santiago, OM
    Kolaczynski, J
    DIABETES CARE, 2005, 28 (03) : 533 - 538
  • [5] A SHORT-TERM COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE U100 AND INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN
    Zhou, L.
    Zhou, N.
    Hu, M.
    VALUE IN HEALTH, 2022, 25 (07) : S386 - S386
  • [6] Glargine versus NPH insulin: Efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes - The glargine and aspart study (GLASS) - A randomised cross-over study
    Chatterjee, S.
    Jarvis-Kay, J.
    Rengarajan, T.
    Lawrence, I. G.
    McNally, P. G.
    Davies, M. J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 77 (02) : 215 - 222
  • [7] Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
    Onishi, Yukiko
    Yamada, Kenichi
    Zacho, Jeppe
    Ekelund, Jan
    Iwamoto, Yasuhiko
    JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (02) : 210 - 217
  • [8] Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China
    James L. Palmer
    Amélie Beaudet
    Jeremy White
    Juliette Plun-Favreau
    Jayne Smith-Palmer
    Advances in Therapy, 2010, 27 : 814 - 827
  • [9] Cost-Effectiveness of Biphasic Insulin Aspart versus Insulin Glargine in Patients with Type 2 Diabetes in China
    Palmer, James L.
    Beaudet, Amelie
    White, Jeremy
    Plun-Favreau, Juliette
    Smith-Palmer, Jayne
    ADVANCES IN THERAPY, 2010, 27 (11) : 814 - 827
  • [10] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Liu, C.
    Tao, L. B.
    Wang, F.
    VALUE IN HEALTH, 2020, 23 : S111 - S111
12345